Regarding the combination of the IMiD with BTZ, preliminary results gathered in in vitro and in vivo models of BTZ-resistant MCL suggested that lenalidomide could partially overcome the resistance to the proteasome inhibitor mediated by the downregulation of IRF4 and MYC [111]. Here, MYC is linked to mantle cell lymphoma.